当前位置: 首页 >> 检索结果
2389. Handling of rescue and missing data affects synthesis and interpretation of evidence: the sodium-glucose cotransporter 2 inhibitor example.
作者: Catharine B Stack.;A Russell Localio.;Michael E Griswold.;Steven N Goodman.;Cynthia D Mulrow.
来源: Ann Intern Med. 2013年159卷4期285-8页
Confidence in evidence summarized in meta-analyses depends on the strength of the underlying studies. This inherent limitation of syntheses appears in the case of a meta-analysis of sodium-glucose cotransporter 2 inhibitors for the treatment of type 2 diabetes because many of the pertinent randomized trials did not handle patient dropout and "rescue" medication properly. Repudiated statistical methods, such as last observation carried forward, and unsophisticated methods for handling postrescue data produce unreliable summary estimates. Future reports of randomized studies and meta-analyses of those studies must focus on posing precise questions about the treatment effect of interest and then implement appropriate statistical methods to account for missing data, patient dropout, and use of rescue medication.
2390. Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
作者: Soheir S Adam.;Jennifer R McDuffie.;Paul F Lachiewicz.;Thomas L Ortel.;John W Williams.
来源: Ann Intern Med. 2013年159卷4期275-84页
Pharmacologic thromboprophylaxis reduces the risk for venous thromboembolism after total hip replacement (THR) or total knee replacement (TKR). New oral anticoagulants (NOACs), including direct thrombin inhibitors and factor Xa inhibitors, are emerging options for thromboprophylaxis after these procedures.
2391. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
作者: Despoina Vasilakou.;Thomas Karagiannis.;Eleni Athanasiadou.;Maria Mainou.;Aris Liakos.;Eleni Bekiari.;Maria Sarigianni.;David R Matthews.;Apostolos Tsapas.
来源: Ann Intern Med. 2013年159卷4期262-74页
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs.
2392. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
作者: Joel Kremer.;Zhan-Guo Li.;Stephen Hall.;Roy Fleischmann.;Mark Genovese.;Emilio Martin-Mola.;John D Isaacs.;David Gruben.;Gene Wallenstein.;Sriram Krishnaswami.;Samuel H Zwillich.;Tamas Koncz.;Richard Riese.;John Bradley.
来源: Ann Intern Med. 2013年159卷4期253-61页
Many patients with rheumatoid arthritis (RA) do not achieve adequate and safe responses with disease-modifying antirheumatic drugs (DMARDs). Tofacitinib is a novel, oral, Janus kinase inhibitor that treats RA.
2393. A home-based intervention to reduce depressive symptoms and improve quality of life in older African Americans: a randomized trial.
作者: Laura N Gitlin.;Lynn Fields Harris.;Megan C McCoy.;Nancy L Chernett.;Laura T Pizzi.;Eric Jutkowitz.;Edward Hess.;Walter W Hauck.
来源: Ann Intern Med. 2013年159卷4期243-52页
Effective care models for treating older African Americans with depressive symptoms are needed.
2394. Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study.
作者: Csaba P Kovesdy.;Anthony J Bleyer.;Miklos Z Molnar.;Jennie Z Ma.;John J Sim.;William C Cushman.;L Darryl Quarles.;Kamyar Kalantar-Zadeh.
来源: Ann Intern Med. 2013年159卷4期233-42页
The ideal blood pressure (BP) to decrease mortality rates in patients with non-dialysis-dependent chronic kidney disease (CKD) is unclear.
2399. Primary care interventions to prevent tobacco use in children and adolescents: U.S. Preventive Services Task Force recommendation statement.
Update of the 2003 U.S. Preventive Services Task Force (USPSTF) recommendation on primary care interventions to prevent tobacco use in children and adolescents.
|